scholarly journals Changes in the Peritoneal Equilibration Test Over the Years in Peritoneal Dialysis Patients and Determination of the Factors Affecting this Change

2020 ◽  
Author(s):  
Hasan SÖZEL ◽  
Fatih YILMAZ ◽  
Feyza BORA ◽  
Yıldız KILAR SÖZEL ◽  
Fettah Fevzi ERSOY
Keyword(s):  
Peritoneal Dialysis ◽  
Dialysis Patients ◽  
Peritoneal Equilibration Test ◽  
Factors Affecting

Peritoneal Equilibration Test Using a Radiopharmaceutical: Diethylenetriaminepentaacetate

2003 ◽  
Vol 23 (2_suppl) ◽  
pp. 31-33
Author(s):  
Raj K. Sharma ◽  
Tarun Jeloka ◽  
Amit Gupta ◽  
Musuvathy S. Senthilnathan ◽  
Prasant K. Pradhan ◽  
...  
Keyword(s):  
Patient Outcome ◽  
Peritoneal Dialysis ◽  
Pilot Study ◽  
Correlation Coefficient ◽  
Important Variable ◽  
Total Clearance ◽  
Peritoneal Membrane ◽  
Peritoneal Equilibration Test ◽  
Membrane Characterization

Background The inherent characteristics of the peritoneal membrane determine the peritoneal dialysis (PD) prescription. Membrane characteristics are also an important variable affecting patient outcome. The peritoneal equilibration test (PET) described by Twardowski and colleagues in 1987 is the most commonly used test for determination of peritoneal membrane characteristics. A need exists to have simpler and more definitive tests of peritoneal membrane characteristics. In a pilot study, we used a radiopharmaceutical [99Tc-diethylenetriaminepentaacetate (99Tc-DTPA)] to determine membrane characteristics. Patients and Methods We injected 99Tc-DTPA (370 MBq) intravenously into 20 patients at the end of peritoneal instillation of 2.5% glucose-containing PD fluid as in a standard PET. After a 4-hour dwell, a dialysate sample was collected, and excretion of 99Tc-DTPA into the dialysate fluid was calculated as a percentage of the injected dose. Depending on the excretion of the radiopharmaceutical into the effluent after intravenous injection, patients were categorized into high, high-average, low-average, and low transporters. An analysis of standard PET characteristics was also conducted for 75 consecutive patients. Results Excretion of the radiopharmaceutical was found to vary between 8% and 17% of the injected dose, depending on membrane characterization. The patients were categorized into four groups depending on the percentage excretion of the radiopharmaceutical: excretion > 15%, high transporter; 12% – 15%, high-average transporter; excretion 10% – 12%, low-average transporter; and excretion < 10%, low transporter. Standard PET characteristics for 75 patients showed 32% to be high transporters, 40% to be high-average transporters, 23% to be low-average transporters, and 5% to be low transporters. The nuclear PET in 20 patients showed 40% to be high transporters, 35% to be high-average transporters, 15% to be low-average transporters, and 10% to be low transporters. Correlation with the standard PET was good (correlation coefficient: 0.64; p = 0.002). Conclusions The nuclear PET could be an alternative to the standard PET for assessing peritoneal membrane characteristics. It is reproducible and may have the added advantages of simplicity and a possibility of measuring total clearance (PD + renal) in the same sitting.

scholarly journals The Peritoneal Equilibration Test Should be Included in Routine Monitoring of Peritoneal Dialysis Patients

2012 ◽  
Vol 32 (2) ◽  
pp. 222-223
Author(s):  
V. Liakopoulos ◽  
O. Nikitidou ◽  
M. Divani ◽  
K. Leivaditis ◽  
G. Antoniadi ◽  
...  
Keyword(s):  
Peritoneal Dialysis ◽  
Dialysis Patients ◽  
Peritoneal Equilibration Test ◽  
Routine Monitoring

Comparison of measuring serum osmolality and equations estimating osmolality in peritoneal dialysis patients

2020 ◽  
Vol 40 (5) ◽  
pp. 509-512
Author(s):  
Kornchanok Vareesangthip ◽  
Andrew Davenport
Keyword(s):  
Peritoneal Dialysis ◽  
Clinical Practice ◽  
Serum Osmolality ◽  
Systematic Bias ◽  
Dialysis Patients ◽  
Limits Of Agreement ◽  
Median Serum ◽  
New Equation ◽  
Osmolar Gap

The osmolar gap increases with kidney failure. A number of equations have been proposed to calculate serum osmolality, allowing determination of the osmolar gap by comparison with measured osmolality. As glucose and icodextrin absorption can potentially interfere with the laboratory measurement of serum sodium, a key component in equations calculating osmolality, we reviewed the performance of 14 equations used to calculate serum osmolality compared to the measurement of serum osmolality in 144 patients with peritoneal dialysis (PD); 81 (56.3%) males, 76 (52.5%) diabetics, mean age of 64.4 ± 16.3 years, 115 (79.9%) prescribed icodextrin and 38 (26.4%) 22.7 g/L glucose dialysates. Measured serum osmolality was 311 (304–320) mosmo/kg (mmol/kg), whereas calculated osmolality for the 14 equations ranged from a median of 274 (269–284) mosmo/kg to 307 (300–316) mosmo/kg. Bland–Altman mean bias showed that measured serum osmolality was greater than the calculated osmolality ranging from 4.0 mosmo/kg to 36.2 mosmo/kg between the 14 equations, with wide 95% limits of agreement (LoA) ranging from −27.1 mosmo/kg to 19.4 mosmo/kg and from −58.5 mosmo/kg to −13.8 mosmo/kg. Only 2 of the 14 equations gave a mean osmolar gap of <10 mosmo/kg and showed no systematic bias, median serum osmolality of 307 (300–316) and 303 (298–312) mosmo/kg, Spearman ρ of 0.57, 0.62, both p < 0.001, respectively. Our study would suggest that only 2 of the 14 equations we compared with measured serum osmolality showed no systematic bias, but still had too great a bias to be useful in clinical practice. As such we propose a new equation to calculate serum osmolality in patients with PD.

Body Surface Area Limitations in Achieving Adequate Therapy in Peritoneal Dialysis Patients

1996 ◽  
Vol 16 (6) ◽  
pp. 617-622 ◽  
Author(s):  
Michael V. Rocco
Keyword(s):  
Peritoneal Dialysis ◽  
Creatinine Clearance ◽  
Surface Area ◽  
Body Surface Area ◽  
Body Surface ◽  
High Dose ◽  
Dialysis Patients ◽  
Ultrafiltration Rate ◽  
Peritoneal Equilibration Test ◽  
Transport Type

Objective To estimate the maximal body surface area (BSA) at which an uric chronic peritoneal dialysis patients can achieve adequate peritoneal dialysis using a variety of continuous ambulatory peritoneal dialysis (CAPD) and cycler regimens. Adequate dialysis was defined as a creatinine clearance of either 60 L/week/1.73 m2 or 70 L/ week/1.73 m2. Design Calculation of daily peritoneal creatinine clearances using standard formulas. For CAPD patients, creatinine clearance was calculated using published values for dialysate-to-plasma ratios for creatinine (DIP cr) measured over a 24-hour period and assuming a daily ultrafiltration rate of 1.5 to 2.0 L/day. For cycler patients, creatinine clearance was calculated for both one and two-hour dwell volumes, using published values for DIP cr from the peritoneal equilibration test and assuming a daily ultrafiltration rate of 2.0 L/day. All clearances were corrected to a normalized body surface area of 1.73 m2. Results For CAPD patients, 2– L dwell volumes can provide a weekly creatinine clearance of 60 L/week/1.73 m2 in patients with BSA < 1.45 m2 in the high transporter group and with BSA < 1.2 m2 in the low-average transporter group. Increasing dwell volume from 2.0 to 2.5 L increases these BSA limits in the four transport groups by 0.2 0.3 m2. Cycler therapy is not a viable option for patients in the low transporter group, and this therapy can achieve adequate creatinine clearances in patients in the low-average transport group only with large dwell volumes and in patients with BSA < 1.55 m2. However, in the high-average and high transporter groups, cycler therapy provides for superior creatinine clearances compared to CAPD patients using similar dwell volumes. Conclusions Adequate creatinine clearances in anuric patients are most likely to be achieved in patients with BSA > 2.0 m2 if they have high-average or high transport characteristics and are receiving cycler therapy with large dwell volumes and at least one daytime dwell. However, adequate creatinine clearances may be difficult to achieve in an uric patients who have a large BSA an d a low or low-average transport type, regardless of peritoneal dialysis modality. These patients should be considered for either high-dose peritoneal dialysis (multiple daytime and nighttime exchanges) or hemodialysis therapy.

Prevalence of Hepatitis c Antibodies (HCV) in a Dialysis Population at One Center

1992 ◽  
Vol 12 (1) ◽  
pp. 28-30 ◽  
Author(s):  
Rafael Selgas ◽  
Rosa Martinez-Zapico ◽  
M. Auxiliadora Bajo ◽  
Jose Ramon Romero ◽  
Jesus Munoz ◽  
...  
Keyword(s):  
Peritoneal Dialysis ◽  
Renal Transplantation ◽  
Hepatitis C ◽  
Hemodialysis Patients ◽  
Test System ◽  
Elisa Test ◽  
Blood Transfusions ◽  
Dialysis Patients ◽  
Specific Antibodies

Hepatitis C (HC) has been recently diagnosed by determination of specific antibodies that represent the former so-called non-A, non-B hepatitis. We studied the prevalence of plasma HCV antibodies among 61 unselected patients on hemodialysis (HD) and 43 on continuous ambulatory peritoneal dialysis (CAPD). Plasma C-antibodies were determined through the ELISA test system. Transfusion policy was the same in both groups. The prevalence of hepatitis C virus antibodies was significantly higher in hemodialysis patients than among those on CAPD. Time on dialysis, previous blood transfusions, and renal transplantation seem to increase the prevalence of C hepatitis antibodies among hemodialy sis patients. The effect of these parameters on CAPD was smaller. Understanding the reasons for these differences may help prevent this disease among dialysis patients.

Sign in / Sign up

Export Citation Format

Share Document